New Daily Persistent Headache
New daily persistent headache (NDPH) is a distinctive primary headache disorder defined by the abrupt onset of a daily headache that is continuous and unremitting from the moment it begins. The patient can typically pinpoint the exact date the headache started. NDPH is one of the most treatment-resistant headache disorders. It may have features mimicking chronic migraine or chronic TTH, but the defining characteristic is the daily-from-onset pattern with a clearly remembered start date. Secondary causes must be exhaustively excluded before making this diagnosis.
Bottom Line
- Defining feature: Daily and continuous headache from onset, with a clearly recalled and identifiable start date. The patient can tell you exactly when the headache began.
- ICHD-3: Headache present daily and unremitting within 24 hours of onset, for >3 months
- Two prognostic subtypes: Self-limiting (resolves within months to 2 years) and refractory (persists for years despite treatment). No way to predict which subtype at onset.
- Diagnosis of exclusion: Must rule out medication overuse, CSF pressure disorders, cerebral venous thrombosis, and other secondary causes first
- Treatment is empiric and often disappointing. No RCTs exist. Try standard migraine or TTH preventives based on the headache phenotype.
- Triggers: Often follows a viral illness, stressful life event, or surgical procedure. EBV and other infections are implicated.
ICHD-3 Criteria (4.10)
- A. Persistent headache fulfilling B and C
- B. Distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours
- C. Present for >3 months
- D. Not better accounted for by another ICHD-3 diagnosis
The headache itself may have migraine-like or TTH-like features. The phenotype is not what defines NDPH — it is the temporal pattern (daily from onset) that is diagnostic.
Clinical Features
| Feature | Details |
|---|---|
| Onset | Abrupt onset of daily headache. Patient can name the exact date. Often starts as a specific headache that simply never goes away. |
| Demographics | Equal sex ratio (unlike migraine). Can occur at any age; two peaks — adolescents/young adults and middle-aged adults. |
| Phenotype | ~60% migraine-like (unilateral, pulsating, photo/phonophobia); ~40% TTH-like (bilateral, pressing). Both phenotypes persist daily from onset. |
| Intensity | Variable. May be moderate at baseline with more severe exacerbations. Some patients report constant severe headache. |
| Prior headache history | May or may not have pre-existing migraine or TTH. The NDPH represents a new, different headache that begins de novo. |
Triggering Events
- Viral illness: 30-50% of cases are preceded by a flu-like or upper respiratory illness. EBV, HSV, CMV, and other viruses have been implicated.
- Stressful life event: ~15-20% report a major life stressor preceding onset
- Surgical procedure: Particularly intubation or procedures in Trendelenburg position (may cause occult CSF leak or cervical strain)
- No identifiable trigger: ~30% have no clear precipitant
Differential Diagnosis
Must Exclude Before Diagnosing NDPH
- Medication overuse headache: If patient began using acute medications frequently after the headache started, MOH may be maintaining it. Withdraw and reassess.
- Spontaneous intracranial hypotension: Orthostatic component may be subtle or lost over time. MRI brain with contrast (pachymeningeal enhancement) is mandatory.
- Cerebral venous sinus thrombosis: MRV should be part of the initial workup
- Elevated ICP (IIH): Check for papilledema; LP if suspected
- Cervical artery dissection: If neck pain preceded the headache onset
- Sphenoid sinusitis: Can cause constant headache mimicking NDPH. CT sinuses if nasal symptoms.
- Chronic meningitis: Low-grade infectious or inflammatory meningitis. CSF analysis if persistent headache + any systemic features.
- Post-infectious: COVID-19-associated persistent daily headache is increasingly recognized and may overlap with NDPH phenotypically.
Recommended Initial Workup for Suspected NDPH
- MRI brain with contrast (exclude mass, pachymeningeal enhancement of SIH, pituitary pathology)
- MRV (exclude venous sinus thrombosis)
- ESR, CRP (exclude inflammatory/vasculitic cause)
- Consider LP: CSF opening pressure (exclude high or low pressure), CSF composition (exclude chronic meningitis)
- Detailed headache diary documenting medication use (exclude MOH)
Proposed Pathophysiology
- Post-infectious neuroinflammation: Viral triggers may activate glial cells and pro-inflammatory cytokines (TNF-α, IL-6) in the trigeminal nucleus and central pain pathways, leading to persistent central sensitization
- Cervical joint hypermobility: May contribute to cervicogenic component in some patients
- Autoimmune mechanism: Some investigators have proposed autoantibodies against neural targets, analogous to autoimmune encephalitis, though this remains speculative
- Persistent glial activation may explain why the headache is resistant to conventional treatments that target neuronal mechanisms
Treatment
There are no randomized controlled trials for NDPH. All treatment recommendations are based on case series, expert opinion, and extrapolation from chronic migraine or chronic TTH evidence.
Prognostic Subtypes
| Subtype | Course | Estimated Frequency |
|---|---|---|
| Self-limiting | Resolves spontaneously within months to 2 years, often without treatment | ~40-50% |
| Refractory | Persists for years despite aggressive treatment with multiple preventive classes | ~50-60% |
Treatment Approach
| Strategy | Agents / Approach | Notes |
|---|---|---|
| Migraine-like phenotype | Amitriptyline, topiramate, venlafaxine, beta-blockers, CGRP mAbs, OnabotulinumtoxinA | Trial each for adequate duration. Response rates are lower than in primary migraine. CGRP mAbs and Botox are used off-label. |
| TTH-like phenotype | Amitriptyline, nortriptyline, mirtazapine | TCAs are the most commonly used agents |
| Nerve blocks | GON block every 2-4 weeks | Worth trying in all phenotypes. May provide temporary relief even in refractory cases. |
| Muscle relaxants | Tizanidine 2-8 mg, cyclobenzaprine 5-10 mg | Adjunct for patients with cervical muscle tension component |
| Anti-inflammatory approach | Doxycycline 100 mg BID (anti-inflammatory effect), naproxen 250-500 mg BID scheduled | Case reports suggest benefit in post-infectious NDPH, possibly by targeting neuroinflammation. Time-limited trial (4-8 weeks). |
| Non-pharmacologic | CBT, biofeedback, physical therapy, exercise | Important adjuncts. CBT addresses pain coping and comorbid mood disorders. |
Practical Approach to NDPH
- Exhaustive exclusion of secondary causes (MRI, MRV, consider LP, labs)
- Classify the phenotype (migraine-like vs TTH-like) and treat accordingly
- Withdraw overused medications if MOH component is present
- Sequential preventive trials: Amitriptyline → topiramate → venlafaxine → CGRP mAb → OnabotulinumtoxinA (if chronic migraine-like). Each for adequate dose and duration before declaring failure.
- Add nerve blocks as adjunct throughout
- Behavioral therapy and exercise from the start
- Counsel on prognosis: Honest discussion that some patients improve over 1-2 years while others are refractory. Realistic goals (improved function, reduced severity) rather than complete resolution.
References
- Rozen TD. New daily persistent headache: an update. Curr Pain Headache Rep. 2014;18(7):431.
- Robbins MS, et al. Treatment of new daily persistent headache. Curr Treat Options Neurol. 2010;12(1):1-13.
- Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22(1):66-69.
- Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
- Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain. 2019;20(1):80.